Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAT2A | P31153 | 2/20 | 0.45 |
| ▸ | METAP2 | P50579 | 1/20 | 0.45 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.41 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5916634 | 0.89 | METAP2 (0.45) | MAT2AMETAP2PDCD1CD274 | |
| SCHEMBL10745150 | 0.87 | METAP2 (0.45) | MAT2AMETAP2 | |
| SCHEMBL10503083 | 0.84 | METAP2 (0.40) | METAP2CD274 | |
| SCHEMBL5916754 | 0.83 | MPI (0.50) | METAP2 | |
| SCHEMBL10502531 | 0.83 | MAT2A (0.40) | MAT2APDCD1CD274 | |
| SCHEMBL5916813 | 0.83 | METAP2 (0.41) | METAP2 | |
| SCHEMBL5916905 | 0.83 | METAP2 (0.48) | METAP2 | |
| SCHEMBL1353489 | 0.82 | METAP2 (0.57) | METAP2 | |
| SCHEMBL30530469 | 0.82 | METAP2 (0.57) | METAP2 | |
| SCHEMBL5916746 | 0.81 | METAP2 (0.53) | METAP2PDCD1CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060135569-A1 | Use of benzisoselenazolone compounds against ischemic myocardial damage | INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2006-06-22 | — | — | US | claimed |
| EP-1541145-A1 | THE USE OF BENZISOSELENAZOLONE COMPOUNDS AGAINST ISCHEMIC MYOCARDIAL DAMAGE | Institute of Materia, Chinese Academy of Medical Sciences (CN) | 2005-06-15 | — | — | EP | claimed |
| US-20060135569-A1 | Use of benzisoselenazolone compounds against ischemic myocardial damage | INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2006-06-22 | — | — | US | disclosed |
| EP-1541145-A1 | THE USE OF BENZISOSELENAZOLONE COMPOUNDS AGAINST ISCHEMIC MYOCARDIAL DAMAGE | Institute of Materia, Chinese Academy of Medical Sciences (CN) | 2005-06-15 | — | — | EP | disclosed |
| EP-0257306-B1 | DISELENOBIS BENZOIC ACID AMIDES OF PRIMARY HETEROCYCLIC AMINES, PROCESS FOR PRODUCING THE SAME AND PHARMACEUTICAL COMPOUNDS COMPRISING THE SAME | A. Nattermann & Cie. GmbH (DE) | 1990-09-12 | — | — | EP | disclosed |
| US-4910313-A | Containing a heterocyclic ring | NATTERMANN & CIE GMBH (DE) | 1990-03-20 | — | — | US | disclosed |
| EP-0154851-B1 | BENZISOSELENAZOLETHIONES,PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL PRODUCTS CONTAINING THESE COMPOUNDS | A. Nattermann & Cie. GmbH (DE) | 1989-08-02 | — | — | EP | disclosed |
| EP-0100899-B1 | BENZISOSELENAZOLONES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | A. Nattermann & Cie. GmbH (DE) | 1988-06-15 | — | — | EP | disclosed |
| EP-0257306-A1 | Diselenobis benzoic acid amides of primary heterocyclic amines, process for producing the same and pharmaceutical compounds comprising the same | A. Nattermann & Cie. GmbH (DE) | 1988-03-02 | — | — | EP | disclosed |
| US-4711961-A | Benzisoselenazolethiones and process for the treatment of various diseases in humans | A. NATTERMANN & CIE GMBH (DE) | 1987-12-08 | — | — | US | disclosed |
| US-4550168-A | Benzisoselenazolones and a process for the treatment of inflammatory diseases | A. NATTERMANN & CIE GMBH (DE) | 1985-10-29 | — | — | US | disclosed |
| EP-0154851-A1 | Benzisoselenazolethiones,process for their preparation and pharmaceutical products containing these compounds | A. Nattermann & Cie. GmbH (DE) | 1985-09-18 | — | — | EP | disclosed |
| EP-0100899-A2 | Benzisoselenazolones, process for their preparation and pharmaceutical compositions containing them | A. Nattermann & Cie. GmbH (DE) | 1984-02-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135569-A1 | Use of benzisoselenazolone compounds against ischemic myocardial damage | TNNI3, TNNT2, MYLK2 | MAT2A 3446/4885METAP2 4321/4885PDCD1 2901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.